ïƒ Info@evomemedical.com  1 (800) 760-6826
EVOME MEDICAL TECHNOLOGIES
Leadership
Mike Seckler
Chief Executive Officer (CEO) of EVOME Medical Technologies
​
Mike Seckler was appointed Permanent Chief Executive Officer (CEO) of EVOME Medical Technologies in July 2023, following one month as interim CEO. He has more than 30 years of life sciences experience commercializing and developing innovative medicines, medical devices, and diagnostics for patients across a wide range of therapeutic areas.
Prior to EVOME, Mike was the COO of FerGene where he was responsible for establishing a groundbreaking joint venture between Blackstone Life Sciences and Ferring International Center SA. He led the global development and commercialization efforts for ADSTILADRIN, an innovative gene therapy approved for the treatment of bladder cancer.
Mike has also held several executive leadership positions with Ferring Pharmaceuticals, a multi-billion-dollar company based in Switzerland, where he was the General Manager of its $100M Canadian subsidiary; Senior Vice President of Global Marketing and Corporate Communications; and Orthopedics Business Unit leader.
Mike honed his expertise at Pfizer and Merck, where he held various leadership positions in marketing, sales, and market access. Mike obtained a B.S. in Health Sciences as well as an M.B.A. from The Pennsylvania State University. He was previously a board member of GlyPharma, a Montreal-based developer of innovative therapeutic medicines, and K2 Biotechnology Ventures, an organization dedicated to founding and operating life science companies emerging from universities.
EVOME MEDICAL TECHNOLOGIES
Board of Directors
.jpg)
.jpg)
.jpg)
Executive Director
Mike Seckler
Chief Executive Officer (CEO) of Salona Global
Mike Seckler was appointed Permanent Chief Executive Officer (CEO) of EVOME Medical Technologies in July 2023, following one month as interim CEO. He has more than 30 years of life sciences experience commercializing and developing innovative medicines, medical devices, and diagnostics for patients across a wide range of therapeutic areas.
Chairman and Executive Director
Ken Kashkin, MD
​COO of Chromocell Corporation
Former CMO, Ferring Pharma (Valued at over US$1B)
Former Sen. Executive at Abbot Laboratories (NYSE:ABT)
Former Vice President at Baxter (NYSE: BAX)
Former Professor, Yale University Medical School
​Dr. Ken Kashkin brings over 30 years of experience in medical devices, research and development, and corporate governance to the board. An expert physician, Dr. Kashkin serves as a technical medical expert on all transactions for the Company. Dr. Kashkin received his undergraduate and medical degrees from University of California, Los Angeles and completed his education at the Yale University School of Medicine.
Non-Executive Director
Lana Newishy
Lana Newishy is a senior executive with over 20 years of cross-functional leadership experience in transformation, operations, strategy and finance with Fortune 500 companies. Her expertise extends to collaborating with top-notch consulting and M&A firms, where she's worked on transformation and acquisition or divestment deals and has had her own practice in the field.
Lana is also an accomplished entrepreneur, having launched and operated two startups, and has a passion for the not-for-profit world where she served as a COO of a global organization.
Outside of her career, Lana enjoys mentoring entrepreneurs at different stages of their business lifecycle and participating in the Alumnae Network for Harvard Women as a steering committee member.
Member of the Board of Directors
Wayne Anderson
Wayne Anderson was appointed to the Board of Directors in February 2024. He is an executive with extensive marketing and general management experience leading small and large companies. He has extensive experience in the pharmaceutical and biopharmaceutical industry at two large companies. At Schering-Plough and Ferring Pharmaceuticals, he had wide range of experience in marketing and sales positions leading up to Vice-President of Marketing and later Vice-President of Marketing/Sales for Oncology Biotech.
He retired as President/CEO of Ferring Pharmaceuticals after working 13 years. He has built Ferring, a smaller biopharmaceutical company from $1MM to over $300MM in the U.S. Launched into a new category in 1997 as an unknown (infertility) and became #1 in Rx’s by 2005. Licensed and launched a second brand into the osteoarthritis space again as an unknown and became #2. Drove product development in the U.S. as Chairman of the U.S. Drug Development. Served on the Ferring Research Institute board for 2 years where he provided needed counsel on the candidacy of products in pre-clinical.
Member of the Board of Directors
William Garbarini
Bill Garbarini was appointed to the Board of Directors in February 2024. A C-level executive with a 30+ year diversified background within the life sciences/pharmaceutical/healthcare industry, Bill’s achievements cover multiple functional areas, from business development and M&A initiatives to operations to product introduction and life cycle management.
​
Recruited by the founders of Conceivable Life Sciences Inc. and TMRW Life Sciences Inc. to start new business to change the way IVF is practiced, Bill helped invent the world’s first automated, robotic storage platform for vitrified embryos and oocytes. In addition, he created the framework for the first automated, laboratory automation system, which will perform all IVF cell manipulations robotically.
​
He served as the COO of Reproductive Medicine Associates of New Jersey to build and grow a national IVF network. Bill’s signature accomplishment with the company was facilitating a merger with the Spanish company Instituto Valenciano de Infertilidad (IVI), thereby creating the world’s largest Assisted Reproduction group and achieving a near $1B valuation.
​
Previously, Bill enjoyed a distinguished 14-year career with Ferring Pharmaceuticals in which he played an instrumental role in the U.S. company’s industry reputation, market position, year-over-year growth, and overall success. As the inaugural head of the Orthopedics Business Unit, Bill introduced Euflexxa, which grew to sales of over $100 million.
​
Bill Garbarini earned his MBA from Fairleigh Dickinson University. An avid runner and soccer enthusiast, he is married with two children and lives in the Greater New York City area.
EVOME MEDICAL TECHNOLOGIES
​Advisors
EVOME Medical Technologies' board and management team brings decades of combined experience in medical device M&A and operational integration. Management's deep industry connections have created a deep and robust pipeline of potential acquisition targets.
​
The Company has retained Michael Dalsin (Former Chairman of PHM) and Roger Greene (Former Vice Chairman of PHM, Harvard Law School, JD) as industry advisors.
​
In addition to the board and advisor driven pipeline, the internal M&A team in the California corporate office systematically searches for potential acquisition targets globally. The internal acquisition team is structured around the key metrics and infrastructure that drove both DJO Global and PHM to success. Using a well-honed 12 point process, our internal M&A team has developed and continues to develop a deep pipeline of acquisition targets.